Onkologie. 2010:4(2):125-126

Results of a long-term clinical trial: extended survival in patients with metastatic prostate

Petr Beneš
Onkologická klinika, Fakultní nemocnice Olomouc

cancer treated with clodronate

Bisphosphonates are part of comprehensive therapeutic strategy in all oncological diagnoses resulting in tumorous bone disease.

Bisphosphonates have been used since the 1980s and are still very beneficial for the patients. The present study evaluated the

benefit of first-generation bisphosphonates, i. e. clodronate, not only in terms of its effect on bone events, but also with respect to

the results of long-term survival of patients. The data from the study confirm that survival was extended in the group of patients

using clodronate.

Keywords: prostate cancer, clodronate, overall survival

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Beneš P. Results of a long-term clinical trial: extended survival in patients with metastatic prostate. Onkologie. 2010;4(2):125-126.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dearnaley D, Sydes M, Mason M, et al. Oral sodium clodronate for metastatic prostate cancer double-blind, placebocontrolled randomised trial: MRC PR05 (ISRCTN38477744). J Natl Cancer Inst 2003; 95: 1300-1311. PubMed. Go to original source... Go to PubMed...
    2. Mason MD, Sydes MR, Glaholm J, et al. Oral sodium clodronate for nonmetastatic prostate cancer results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007; 99: 765-776. CrossRef |PubMed. Go to original source... Go to PubMed...
    3. Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009; 45: 1909-1915. CrossRef |PubMed. Go to original source... Go to PubMed...
    4. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004; 11: 207-224. CrossRef |PubMed. Go to original source... Go to PubMed...
    5. Pavlík I. Podávání bisfosfonátů u pacientů s karcinomem prostaty metastazujícím do kostí. Farmakoterapie 2007; 4: 403-409.
    6. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721-723. CrossRef |PubMed. Go to original source... Go to PubMed...
    7. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-1244. CrossRef |PubMed. Go to original source... Go to PubMed...
    8. Lee YP, Schwarz EM, Davies M, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002; 62: 5564-5570. PubMed. Go to PubMed...
    9. Fleisch H. Bisphosphonate in bone disease. Academic press, San Diego, San Francisco, 2000: 212.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.